Xianzhu Yang

Xianzhu Yang

Auto-generated profile, based on publicly available information

Xianzhu Yang

School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P. R. China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HLHongjun Li
Hongjun Li
JDJin-Zhi Du
Jin-Zhi Du
XDXiao-Jiao Du
Xiao-Jiao Du
CXCong-Fei Xu
Cong-Fei Xu
CSChun-Yang Sun
Chun-Yang Sun
JWJun Wang
Jun Wang
Significance: Successively overcoming a series of biological barriers that cancer nanotherapeutics would encounter upon intravenous administration is required for achieving positive treatment outcomes. A hurdle to this goal is the inherently unfavorable tumor penetration of nanoparticles due to their relatively large sizes. We developed a stimuli-responsive clustered nanoparticle (iCluster) and justified that its adaptive alterations of physicochemical properties (e.g. size, zeta potential, and drug release rate) in accordance with the endogenous stimuli of the tumor microenvironment made possible the ultimate overcoming of these barriers, especially the bottleneck of tumor penetration. Results in varying intractable tumor models demonstrated significantly improved antitumor efficacy of iCluster than its control groups, demonstrating that overcoming these delivery barriers can be achieved by innovative nanoparticle design.

28 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMin Li
Min Li
SLShuya Li
Shuya Li
HZHan Zhou
Han Zhou
XTXinfeng Tang
Xinfeng Tang
YWYi Wu
Yi Wu
YWYucai Wang
Yucai Wang
The efficacy of nano-mediated drug delivery has been impeded by multiple biological barriers such as the mononuclear phagocyte system (MPS), as well as vascular and interstitial barriers. To overcome the abovementioned obstacles, we report a nano-pathogenoid (NPN) system that can in situ hitchhike circulating neutrophils and supplement photothermal therapy (PTT). Cloaked with bacteria-secreted outer membrane vesicles inheriting pathogen-associated molecular patterns of native bacteria, NPNs are effectively recognized and internalized by neutrophils. The neutrophils migrate towards inflamed tumors, extravasate across the blood vessels, and penetrate through the tumors. Then NPNs are rapidly released from neutrophils in response to inflammatory stimuli and subsequently taken up by tumor cells to exert anticancer effects. Strikingly, due to the excellent targeting efficacy, cisplatin-loaded NPNs combined with PTT completely eradicate tumors in all treated mice. Such a nano-platform represents an efficient and generalizable strategy towards in situ cell hitchhiking as well as enhanced tumor targeted delivery.

9 January 2018 in ACS Nano
Verified
Journal Article
Closed access
YLYing-Li Luo
Ying-Li Luo
CXCong-Fei Xu
Cong-Fei Xu
HLHongjun Li
Hongjun Li
ZCZhi-Ting Cao
Zhi-Ting Cao
JLJing Liu
Jing Liu
JWJun Wang
Jun Wang

1 February 2018 in Biomaterials
Verified
Journal Article
Closed access
ZCZiyang Cao
Ziyang Cao
LFLiangzhu Feng
Liangzhu Feng
GZGuobing Zhang
Guobing Zhang
JWJunxia Wang
Junxia Wang
SSSong Shen
Song Shen
XYXianzhu Yang
Xianzhu Yang

1 January 2019 in Biomaterials
Verified
Journal Article
Closed access
PPPei Pei
Pei Pei
CSChunyang Sun
Chunyang Sun
WTWei Tao
Wei Tao
JLJie Li
Jie Li
XYXianzhu Yang
Xianzhu Yang
JWJun Wang
Jun Wang

5 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
CXCongfei Xu
Congfei Xu
ZLZidong Lu
Zidong Lu
YLYingli Luo
Yingli Luo
YLYang Liu
Yang Liu
ZCZhiting Cao
Zhiting Cao
JWJun Wang
Jun Wang
The NLRP3 inflammasome is a well-studied target for the treatment of multiple inflammatory diseases, but how to promote the current therapeutics remains a large challenge. CRISPR/Cas9, as a gene editing tool, allows for direct ablation of NLRP3 at the genomic level. In this study, we screen an optimized cationic lipid-assisted nanoparticle (CLAN) to deliver Cas9 mRNA (mCas9) and guide RNA (gRNA) into macrophages. By using CLAN encapsulating mCas9 and gRNA-targeting NLRP3 (gNLRP3) (CLANmCas9/gNLRP3), we disrupt NLRP3 of macrophages, inhibiting the activation of the NLRP3 inflammasome in response to diverse stimuli. After intravenous injection, CLANmCas9/gNLRP3 mitigates acute inflammation of LPS-induced septic shock and monosodium urate crystal (MSU)-induced peritonitis. In addition, CLANmCas9/gNLRP3 treatment improves insulin sensitivity and reduces adipose inflammation of high-fat-diet (HFD)-induced type 2 diabetes (T2D). Thus, our study provides a promising strategy for treating NLRP3-dependent inflammatory diseases and provides a carrier for delivering CRISPR/Cas9 into macrophages.